Overview
Rainbow Extension Study
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-05-18
2022-05-18
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Ranibizumab
Criteria
Inclusion Criteria:- The patient successfully completed the core study CRFB002H2301
- The patient received study treatment in both eyes at baseline of study CRFB002H2301
Exclusion Criteria:
- Patient has a medical condition or personal circumstance which precludes study
participation or compliance with study procedures, as assessed by the Investigator
- Patient has been discontinued from the core study CRFB002H2301 at any time
Other protocol-defined inclusion/exclusion criteria may apply